ストックスクリーナーアプリを入手
10.26
9.38%
0.88
プレマーケット:
10.26
Moonlake Immunotherapeutics (MLTX) 最新ニュース
Lost Money on MoonLake Immunotherapeutics (MLTX)? Contact Levi & Korsinsky to Protect Your Rights - ACCESS Newswire
Chief Financial Officer of MoonLake Immunotherapeutics Matthias Bodenstedt Buys 1.8% More Shares - Yahoo
Why Are MoonLake's (MLTX) Trial Setbacks Raising New Questions About Management Credibility and Regulatory Risks? - simplywall.st
MoonLake Immunotherapeutics (NASDAQ:MLTX) Shares Gap UpShould You Buy? - MarketBeat
MLTX SECURITIES NOTICE: MoonLake Immunotherapeutics Securities Fraud Investigation is Pending – Contact BFA Law if You Lost Money - GlobeNewswire
CFO Makes Bold Move with Major Stock Purchase in MoonLake Immunotherapeutics - TipRanks
MOONLAKE IMMUNOTHERAPEUTICS REMINDER: Bragar Eagel & - GlobeNewswire
Insider Stock Purchases: October 09, 2025 - Quiver Quantitative
MoonLake Immunotherapeutics Stock (MLTX) Opinions on Phase 3 Trial Setback - Quiver Quantitative
Insider Buying: Matthias Bodenstedt Acquires Shares of MoonLake Immunotherapeutics - GuruFocus
Bodenstedt, MoonLake CFO, buys $98k in MLTX stock - Investing.com
Bodenstedt, MoonLake CFO, buys $98k in MLTX stock By Investing.com - Investing.com UK
BFA Law is Investigating MoonLake Immunotherapeutics (MLTX) for Securities Fraud and Urges Shareholders to Contact the Firm - Newsfile
Measuring MoonLake Immunotherapeutics’s beta against major indicesFed Meeting & Daily Growth Stock Tips - newser.com
MoonLake Immunotherapeutics (MLTX) Faces Investor Scrutiny - GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of MoonLake ImmunotherapeuticsMLTX - PR Newswire
MLTX SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates - GlobeNewswire
MLTX INQUIRY NOTICE: MoonLake Immunotherapeutics Hit with - GlobeNewswire
MLTX INVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of MoonLake Immunotherapeutics - Newsfile
Rosen Law Firm Encourages MoonLake Immunotherapeutics Investors to Inquire About Securities Class Action InvestigationMLTX - Barchart.com
MOONLAKE INVESTIGATION ALERT: Bragar Eagel & Squire, P.C. - GlobeNewswire
MOONLAKE INVESTIGATION ALERT: Bragar Eagel & Squire, P.C. Reminds Investors of the Investigation into MoonLake Immunotherapeutics and Encourages Investors to Contact the Firm - GlobeNewswire Inc.
MLTX ALERT: Levi & Korsinsky Investigates MoonLake Immunotherapeutics on Behalf of Shareholders Who Lost Money - ACCESS Newswire
Oppenheimer lowers Moonlake Immunotherapeutics stock price target after mixed trial results - Investing.com
Oppenheimer Maintains MoonLake Immunotherapeutics(MLTX.US) With Buy Rating, Cuts Target Price to $25 - 富途牛牛
MLTX SHAREHOLDER NOTICE: MoonLake Immunotherapeutics - GlobeNewswire
MoonLake Immunotherapeutics Investors Should Contact Block - GlobeNewswire
MLTX Investor News: If You Have Suffered Losses in MoonLake - GlobeNewswire
MLTX ACTIVE INVESTIGATION: Lost Money on MoonLake Immunotherapeutics? Contact Levi & Korsinsky Now - ACCESS Newswire
Levi & Korsinsky Investigates Possible Securities Fraud by MoonLake Immunotherapeutics (MLTX) - ACCESS Newswire
MLTX Investors Have Opportunity to Join MoonLake Immunotherapeutics Fraud Investigation with the Schall Law Firm - The Malaysian Reserve
MoonLake Immunotherapeutics Investigated for Securities Fraud ViolationsContact the DJS Law Group to Discuss Your RightsMLTX - MarketScreener
MoonLake Immunotherapeutics (NASDAQ:MLTX) Shares Up 9.9%Should You Buy? - MarketBeat
What is HC Wainwright’s Forecast for MLTX FY2025 Earnings? - Defense World
MoonLake Immunotherapeutics Investors Should Contact Block & Leviton to Find Out How They Might Recover Losses Through The Firm’s Investigation - GlobeNewswire
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against MoonLake Immunotherapeutics (MLTX) And Encourages Investors to Reach Out - ACCESS Newswire
MoonLake Immunotherapeutics (MLTX): Valuation in Focus After VELA HS Trial Setback and Market Scrutiny - simplywall.st
Top 3 Health Care Stocks That Are Preparing To Pump In Q4 - Benzinga
Leading vs lagging indicators on MoonLake Immunotherapeutics performance2025 Fundamental Recap & Technical Buy Zone Confirmation - newser.com
MLTX INVESTOR NOTICE: Faruqi & Faruqi, LLP Investigates Claims on - The National Law Review
Ongoing MoonLake Immunotherapeutics (MLTX) Investigation: Protect Your RightsContact Levi & Korsinsky - ACCESS Newswire
Combining price and volume data for MoonLake ImmunotherapeuticsRisk Management & Daily Profit Focused Screening - newser.com
What earnings revisions data tells us about MoonLake ImmunotherapeuticsSwing Trade & AI Driven Stock Price Forecasts - newser.com
MoonLake Immunotherapeutics results for Phase 3 VELA-1, VELA-2 trials - MSN
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against MoonLake Immunotherapeutics (MLTX) And Encourages Stockholders to Reach Out - ACCESS Newswire
ATTENTION MLTX Shareholders: Lost Money on MoonLake Immunotherapeutics? Contact Levi & Korsinsky About Investigation - ACCESS Newswire
Did MoonLake Immunotherapeutics (MLTX) Mislead Investors? Levi & Korsinsky Investigates - ACCESS Newswire
The week in pharma: action, reaction and insight – week to October 3 - The Pharma Letter
Is MoonLake Immunotherapeutics stock a buy before product launchesJuly 2025 Opening Moves & Community Verified Watchlist Alerts - newser.com
Published on: 2025-10-05 03:26:36 - newser.com
MoonLake Immunotherapeutics Reports Positive Phase 3 Trial Results - MSN
MLTX LEGAL NOTICE: MoonLake Immunotherapeutics Faces - GlobeNewswire
LifeSci Capital Maintains MoonLake Immunotherapeutics(MLTX.US) With Buy Rating, Cuts Target Price to $16 - 富途牛牛
MoonLake Immunotherapeutics (MLTX): Assessing Valuation Following Phase 3 Trial Miss and Legal Scrutiny - Yahoo Finance
MLTX LEGAL NOTICE: MoonLake Immunotherapeutics Faces Securities Fraud Investigation due to Drug Trial Results – Contact BFA Law if You Lost Money - GlobeNewswire
MoonLake Immunotherapeutics (MLTX) Stock Price | Live Quotes & Charts | NSC - StocksToTrade
MLTX Investor ALERT: Block & Leviton Investigating MoonLake Immunotherapeutics For Securities Fraud; Investors Should Contact The Firm To Potentially Recover Losses - ACCESS Newswire
Why MoonLake Immunotherapeutics (MLTX) Is Down 86.8% After Sonelokimab Phase 3 Trial Misses Key Goal - simplywall.st
5.74%
大文字化:
|
ボリューム (24 時間):